Registration for this event has been suspended.

Event Details

Online Registration has been closed. Please go to onsite registration desk for your registration
China’s new drug R&D is growing vigorously with the stimulus of capitals. Despite many breakthroughs in high-throughput omics, a deeper understanding of disease biology, and increased investments in R&D, the delivery of innovative therapies to patients in need is still far behind the expectation, with significant hurdles during translation from basic research to clinical application. The solution is to set up an expressway from Bench to Bedside. Nowadays, China’s medicine industry has undertaken significant transition. With the unprecedented regulatory reform occurred in China CFDA, drug administration has taken a huge and solid step in supporting innovation, truth, integrity, and science. China’s pharmaceutical industry faces a future development path on how to transform the latest innovative scientific research fruits into highly efficacious and safer therapies to patients. While, in realizing the future development path, we need to consider how to conduct early-stage research, evaluation, and confirmation of innovative medicines more scientifically, how to successfully translate early-stage R&D results into licensed drugs that can be traded in markets, and how to implement the early-stage R&D fruits in an appropriate business model?
As a global public-benefit academic organization, DIA has made outstanding contribution in driving interaction and exchange among scientific researchers, clinical doctors, innovative medicine developers, and drug administration management, jointly facilitating sound development of the industry, and better meeting patients’ clinical demands. It is exactly such scientific, objective, transparent, and equal exchange atmosphere that enables many industry experts and scholars to initiatively participate in the organizing work of DIA innovation meeting. Therefore, it is hoped that our common efforts may bring some fruits to participants.
Following the big success of the past 2 years ,DDI bring together more than 500 innovators and key thought leaders every year.  DIA China will join hands with BioBAY again --- the most influential & innovative Science Park in China to hold the 3rd Drug Discovery Innovation Conference in Suzhou on Sept.26-28
The theme of this conference is Translational Medicine--- Building a Bridge from Bench to Bedside.  DIA will conduct a series of in-depth discussions of such hotspot issues as early-stage research innovation, talent education system planning, advances in translational medicine, early-stage clinical research design, innovation review, MAH implementation, and local innovation. 
Target Audiences
  • Senior management of worldwide biotech and pharmaceuticals companies, CROs, and CMOs companies
  • Early-stage Pharmaceutical R&D scientists, professors of research institutes and universities
  • Senior management of medicine, biotech, investment
  • Early-stage R&D device, service and solution providers
  • Governmental officials of drug administration and staffs of legal departments of enterprises
  • Lawyers and patent attorneys
  • Developers of Science Park